Jian Li, MD
Pulmonary Disease · Tifton, GANPI 1184705097
Payments from drug & device makers
Across 697 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$842
- Sanofi$818
- Mallinckrodt Hospital Products Inc.$817
- plus $5K from 31 others
What the payments were for
- Food & beverage$12,38598%
- Education$2342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 202 | $3,104 |
| AstraZeneca | 77 | $1,295 |
| Boehringer Ingelheim | 56 | $1,054 |
| Regeneron Healthcare Solutions, Inc. | 31 | $842 |
| Sanofi | 34 | $818 |
| Mallinckrodt Hospital Products Inc. | 41 | $817 |
| Mylan Specialty L.p. | 43 | $729 |
| Insmed, Inc. | 37 | $693 |
| Sunovion Pharmaceuticals Inc. | 44 | $592 |
| Actelion Pharmaceuticals US, Inc. | 18 | $452 |
| Grifols USA, LLC | 18 | $370 |
| Merck | 12 | $234 |
| ANI Pharmaceuticals, Inc. | 10 | $210 |
| Verona Pharma, Inc. | 15 | $200 |
| Bayer | 10 | $195 |
| Amgen | 7 | $153 |
| Philips North America LLC | 8 | $131 |
| Fisher & Paykel Healthcare Inc | 2 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| United Therapeutics Corporation | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Novartis | 3 | $48 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| AbbVie(2 entities) | 2 | $40 |
| Johnson & Johnson(2 entities) | 2 | $40 |
| Inogen, Inc. | 1 | $33 |
| Edwards Lifesciences | 1 | $32 |
| Intuitive Surgical | 2 | $28 |
| Baxter Healthcare | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Pfizer | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
How this compares
$12,619 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 496 | $613,654 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 293 | $319,902 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $232,272 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $82,387 |
| Spiriva RespimatTiotropium Bromide | 50 | $54,314 |
| Dupixent SyringeDupilumab | 11 | $42,057 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $33,032 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $30,981 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $30,899 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $25,582 |
| Ambrisentan | 12 | $14,925 |
| Spiriva HandihalerTiotropium Bromide | 15 | $13,511 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 323 | $12,825 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $10,405 |
| Theophylline ErTheophylline Anhydrous | 155 | $10,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,104 | $732,899666 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,295 | $352,933368 claims |
| Grifols USA, LLCProlastin C | $370 | $232,27213 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,054 | $85,21376 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Tifton
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.